The company's principal activity was to exploit new enabling technologies to advance and shorten the new drug development cycle. As the company was unsuccessful at advancing research programs, it decided to focus on developing and marketing products to physicians practicing in specialist areas and entered into an agreement and plan of merger and reorganization with innovative drug delivery systems. This proposed merger had significant shareholder opposition and hence, both the companies reached a mutual decision to terminate the merger effort and completed it. During 2003, it discontinued its drug discovery operations and terminated all research activities in which it was involved before and began identifying potential business opportunities.
Executive Information
Name
Title
Email
John Paganelli
Chmn., Interim CEO
N/A
Adam Logal
Exec. Dir. - Finance, Chief Accounting Officer, Treasurer
